Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
Non-regulated information
Biocartis Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer
Non-regulated information
Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla Cartridge Sold and 2,000th Idylla Instrument Placed
Non-regulated information
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
Non-regulated information
Biocartis Announces Presentation of Three Idylla Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Non-regulated information
Biocartis Announces Presentation of First Prospective Validation Study Data of Merlin Test by Partner SkylineDx at EADO 2022 Conference
Non-regulated information
Biocartis and Ophiomics to Collaborate on Liver Cancer Test
Non-regulated information
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes